Literature DB >> 33838580

Clinical Features and Outcomes of Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Infants and Toddlers.

Changhong Ren1, Weihua Zhang1, Xiaotun Ren1, Jiuwei Li1, Changhong Ding1, Xiaohui Wang1, Haitao Ren2, Fang Fang3.   

Abstract

OBJECTIVE: We describe the clinical features and outcomes of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in infants and toddlers.
METHODS: This was a single-center retrospective study. Infants and toddlers who met the diagnostic criteria for anti-NMDAR encephalitis were recruited for the study. Data on clinical features, treatment, and long-term outcomes were collected retrospectively.
RESULTS: A total of 41 patients (age range: six to 34 months; median age: 23 months; female: 19) were enrolled in this study. Nineteen (46%) patients exhibited classical anti-NMDAR encephalitis, whereas 22 (54%) patients exhibited anti-NMDAR encephalitis after viral encephalitis. There was a high presentation of movement disorders (100%), developmental regression (90%), abnormal behaviors (90%). All patients were administered first-line therapy, with only 17% of them being administered second-line immunotherapy. Two patients succumbed to the disease, whereas none of them relapsed. At the long-term follow-up (more than one year), 20 of 35 (57%) exhibited satisfactory outcomes (modified Rankin Scale ≤2). Compared with patients with classical anti-NMDAR encephalitis (n = 18), patients after viral encephalitis (n = 17) were more likely to have worse clinical outcomes. They exhibited a higher modified Rankin Scale/Pediatric Cerebral Performance Category score and more frequent seizures. A predictor of poor outcome was presentation after viral encephalitis (odds ratio 35.7, 95% confidence interval 4.64 to 275.03, P = 0.001).
CONCLUSION: Anti-NMDAR encephalitis in infants and toddlers clinically presents with movement disorders, developmental regression, and abnormal behaviors. Interestingly, this group had a higher proportion of patients after viral encephalitis, which is regarded as the only risk factor for poor outcomes.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-N-methyl-d-aspartate receptor; Encephalitis; Infants; Outcome; Pediatric; Toddlers; Viral encephalitis

Mesh:

Year:  2021        PMID: 33838580     DOI: 10.1016/j.pediatrneurol.2021.02.009

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  2 in total

1.  External Assessment of the Anti-N-Methyl-D-Aspartate Receptor Encephalitis One-Year Functional Status Score in Chinese Pediatric Patients.

Authors:  Hanyu Luo; Yuhang Li; Yaxin Zheng; Lvli Zhou; Jiaxin Yang; Zhixu Fang; Yan Jiang; Juan Wang; Zhengxiong Yao; Min Chen; Li Jiang
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

2.  Emphasizing Pulmonary Function With Respiratory Therapy in an Infant With Congenital Adrenal Hyperplasia, Bronchopneumonia and Leptomeningitis.

Authors:  Pratik R Jaiswal; Pallavi Bhakaney; Vaishnavi Yadav; Moli Jain; Vishnu Vardhan
Journal:  Cureus       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.